+44 7393 450837
hello@adamfayed.com

Reseña de Eden Pharma

🌐 English | Vedi in Italiano

Esta publicación examinará Eden Pharma y el mercado del cannabis en el que opera.

Con sede en Londres, Eden Pharma Ltd es una empresa independiente de investigación y desarrollo de cannabis fundada en 2017 por el reconocido escritor y experto en cannabis Martin Booth.

Los costos de investigación y desarrollo pueden ser altos, pero Eden Pharma está comprometida con priorizar la investigación del cannabis para usos innovadores.

Si deseas invertir como expatriado o persona con alto patrimonio, que es mi especialidad, puedes escribirme (hello@adamfayed.com) o usar WhatsApp (+44-7393-450-837).

Los inversores que estén considerando invertir en cannabis encontrarán útil esta reseña.

Sin embargo, este tipo de inversiones conllevan altos riesgos y podrías perder todo tu dinero.

¿Quién es Eden Pharma?

La empresa se dedica a la producción y venta de cepas personalizadas de cannabis para usos médicos y recreativos. Además, desarrolla productos innovadores de salud y belleza como suplementos alimenticios, bebidas infusionadas y cosméticos.

Potencial de Crecimiento de Eden Pharma

Dado su posicionamiento estratégico, Eden Pharma tiene un gran potencial en el sector de la marihuana medicinal. Su valor de mercado alcanzó aproximadamente 774 millones de libras en octubre de 2022.

Ese mismo año, Eden Pharma adquirió un terreno de 5.000 acres en Uganda para potenciar sus esfuerzos en I+D. El gobierno de Uganda otorgó autorización completa a la instalación, que se considera la más grande de su tipo en el mundo, para la producción de CBD y cannabis con fines de exportación.

Desafíos de Eden Pharma

Las leyes varían en cada jurisdicción y suelen imponer controles estrictos al cannabis medicinal. Cumplir con estas normativas representa un desafío constante.

Eden Pharma compite en un mercado saturado, donde diferenciarse es difícil.

Los cambios legislativos, interrupciones en la cadena de suministro y las preferencias del consumidor hacen que el mercado del cannabis sea volátil e incierto.

Equilibrar la inversión en investigación con la rentabilidad es también un reto financiero.

El Mercado del Cannabis

Se estima que para 2027 el mercado mundial del cannabis alcanzará los 82.300 millones de dólares.

América del Norte lidera el mercado debido al uso médico generalizado y la legalización en numerosos estados de EE.UU.

La aceptación social, nuevos productos, avances tecnológicos y más investigación impulsan el crecimiento del mercado.

Ventajas y riesgos de invertir en cannabis

Ventajas de invertir en cannabis

  • Opciones Diversas: El sector médico del cannabis ofrece múltiples oportunidades, desde la producción primaria hasta productos derivados como tés, vaporizadores, tabletas y comestibles.
  • Tendencias Prometedoras: El crecimiento del mercado y el reconocimiento médico del cannabis presentan oportunidades atractivas.
  • Expansión de Marcas: Las empresas multijurisdiccionales ayudan a las marcas a crecer superando restricciones legales.

Riesgos de invertir en cannabis

  • Ambigüedad Legal: La falta de regulación clara, especialmente en EE.UU., hace que el sector sea altamente especulativo.
  • Obstáculos Regulatorios: Las complejas normativas dificultan la inversión segura.
  • Volatilidad del Mercado: Cambios en el consumidor, interrupciones en la cadena de suministro y nuevas leyes afectan negativamente.
  • Sector Especulativo: El panorama legal inestable convierte esta inversión en una apuesta de alto riesgo.

Pained by financial indecision?

Adam Fayed Contact CTA3

Adam is an internationally recognised author on financial matters with over 830million answer views on Quora, a widely sold book on Amazon, and a contributor on Forbes.

This website is maintained for personal branding purposes and is intended solely to share the personal views, experiences, as well as personal and professional journey of Adam Fayed.

Personal Capacity
All views, opinions, statements, insights, or declarations expressed on this website are made by Adam Fayed in a strictly personal capacity. They do not represent, reflect, or imply any official position, opinion, or endorsement of any organization, employer, client, or institution with which Adam Fayed is or has been affiliated. Nothing on this website should be construed as being made on behalf of, or with the authorization of, any such entity.

Endorsements, Affiliations or Service Offerings
Certain pages of this website may contain general information that could assist you in determining whether you might be eligible to engage the professional services of Adam Fayed or of any entity in which Adam Fayed is employed, holds a position (including as director, officer, employee or consultant), has a shareholding or financial interest, or with which Adam Fayed is otherwise professionally affiliated. However, any such services—whether offered by Adam Fayed in a professional capacity or by any affiliated entity—will be provided entirely separately from this website and will be subject to distinct terms, conditions, and formal engagement processes. Nothing on this website constitutes an offer to provide professional services, nor should it be interpreted as forming a client relationship of any kind. Any reference to third parties, services, or products does not imply endorsement or partnership unless explicitly stated.

*Many of these assets are being managed by entities where Adam Fayed has personal shareholdings but whereby he is not providing personal advice.

I confirm that I don’t currently reside in the United States, Puerto Rico, the United Arab Emirates, Iran, Cuba or any heavily-sanctioned countries.

If you live in the UK, please confirm that you meet one of the following conditions:

1. High-net-worth

I make this statement so that I can receive promotional communications which are exempt

from the restriction on promotion of non-readily realisable securities.

The exemption relates to certified high net worth investors and I declare that I qualify as such because at least one of the following applies to me:

I had, throughout the financial year immediately preceding the date below, an annual income

to the value of £100,000 or more. Annual income for these purposes does not include money

withdrawn from my pension savings (except where the withdrawals are used directly for

income in retirement).

I held, throughout the financial year immediately preceding the date below, net assets to the

value of £250,000 or more. Net assets for these purposes do not include the property which is my primary residence or any money raised through a loan secured on that property. Or any rights of mine under a qualifying contract or insurance within the meaning of the Financial Services and Markets Act 2000 (Regulated Activities) order 2001;

  1. c) or Any benefits (in the form of pensions or otherwise) which are payable on the

termination of my service or on my death or retirement and to which I am (or my

dependents are), or may be entitled.

2. Self certified investor

I declare that I am a self-certified sophisticated investor for the purposes of the

restriction on promotion of non-readily realisable securities. I understand that this

means:

i. I can receive promotional communications made by a person who is authorised by

the Financial Conduct Authority which relate to investment activity in non-readily

realisable securities;

ii. The investments to which the promotions will relate may expose me to a significant

risk of losing all of the property invested.

I am a self-certified sophisticated investor because at least one of the following applies:

a. I am a member of a network or syndicate of business angels and have been so for

at least the last six months prior to the date below;

b. I have made more than one investment in an unlisted company in the two years

prior to the date below;

c. I am working, or have worked in the two years prior to the date below, in a

professional capacity in the private equity sector, or in the provision of finance for

small and medium enterprises;

d. I am currently, or have been in the two years prior to the date below, a director of a company with an annual turnover of at least £1 million.

 

Adam Fayed is not UK based nor FCA-regulated.

 

Adam Fayed uses cookies to enhance your browsing experience, deliver personalized content based on your preferences, and help us better understand how our website is used. By continuing to browse adamfayed.com, you consent to our use of cookies.


Learn more in our Privacy Policy & Terms & Conditions.